JP2020531505A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531505A5
JP2020531505A5 JP2020510595A JP2020510595A JP2020531505A5 JP 2020531505 A5 JP2020531505 A5 JP 2020531505A5 JP 2020510595 A JP2020510595 A JP 2020510595A JP 2020510595 A JP2020510595 A JP 2020510595A JP 2020531505 A5 JP2020531505 A5 JP 2020531505A5
Authority
JP
Japan
Prior art keywords
methyl
urea
methylpiperidin
difluorophenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020510595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531505A (ja
JP7297738B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/000354 external-priority patent/WO2019040107A1/en
Publication of JP2020531505A publication Critical patent/JP2020531505A/ja
Publication of JP2020531505A5 publication Critical patent/JP2020531505A5/ja
Priority to JP2023097704A priority Critical patent/JP7628578B2/ja
Application granted granted Critical
Publication of JP7297738B2 publication Critical patent/JP7297738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020510595A 2017-08-21 2018-08-20 疾患の治療のための化合物、その塩、及び方法 Active JP7297738B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097704A JP7628578B2 (ja) 2017-08-21 2023-06-14 疾患の治療のための化合物、その塩、及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762548301P 2017-08-21 2017-08-21
US62/548,301 2017-08-21
SE1730225-8 2017-08-24
SE1730225 2017-08-24
PCT/US2018/000354 WO2019040107A1 (en) 2017-08-21 2018-08-20 COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097704A Division JP7628578B2 (ja) 2017-08-21 2023-06-14 疾患の治療のための化合物、その塩、及び方法

Publications (3)

Publication Number Publication Date
JP2020531505A JP2020531505A (ja) 2020-11-05
JP2020531505A5 true JP2020531505A5 (cg-RX-API-DMAC10.html) 2021-09-24
JP7297738B2 JP7297738B2 (ja) 2023-06-26

Family

ID=63840976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020510595A Active JP7297738B2 (ja) 2017-08-21 2018-08-20 疾患の治療のための化合物、その塩、及び方法
JP2023097704A Active JP7628578B2 (ja) 2017-08-21 2023-06-14 疾患の治療のための化合物、その塩、及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023097704A Active JP7628578B2 (ja) 2017-08-21 2023-06-14 疾患の治療のための化合物、その塩、及び方法

Country Status (22)

Country Link
US (3) US11345693B2 (cg-RX-API-DMAC10.html)
EP (2) EP3672954B1 (cg-RX-API-DMAC10.html)
JP (2) JP7297738B2 (cg-RX-API-DMAC10.html)
KR (1) KR102692233B1 (cg-RX-API-DMAC10.html)
CN (2) CN111132976B (cg-RX-API-DMAC10.html)
AU (1) AU2018321546B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020003477A2 (cg-RX-API-DMAC10.html)
CA (1) CA3071644A1 (cg-RX-API-DMAC10.html)
DK (1) DK3672954T3 (cg-RX-API-DMAC10.html)
ES (1) ES3042110T3 (cg-RX-API-DMAC10.html)
FI (1) FI3672954T3 (cg-RX-API-DMAC10.html)
HU (1) HUE073569T2 (cg-RX-API-DMAC10.html)
IL (1) IL272444B (cg-RX-API-DMAC10.html)
LT (1) LT3672954T (cg-RX-API-DMAC10.html)
MX (1) MX2020001757A (cg-RX-API-DMAC10.html)
PL (1) PL3672954T3 (cg-RX-API-DMAC10.html)
PT (1) PT3672954T (cg-RX-API-DMAC10.html)
RS (1) RS67273B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202001062XA (cg-RX-API-DMAC10.html)
SI (1) SI3672954T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019040107A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202001717B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040107A1 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
PL3741744T3 (pl) * 2019-05-22 2022-04-25 Zakłady Farmaceutyczne "Polpharma" S.A. Farmaceutyczny produkt pośredni do wytwarzania pimawanseryny
EP3906969A4 (en) * 2019-06-12 2023-11-22 Tao Pharmaceutical (Suzhou) Co., Ltd. ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF
CN115677723B (zh) * 2020-01-21 2024-06-04 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
WO2021147818A1 (zh) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
CN111548257B (zh) * 2020-05-28 2022-11-15 安道麦马克西姆有限公司 一种(4-异丙氧基-2-甲基)苯基异丙基酮的制备方法
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
WO2022145408A1 (ja) * 2020-12-28 2022-07-07 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体
CN113292484B (zh) * 2021-06-04 2022-11-15 沈阳药科大学 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
ES3066682T3 (en) * 2021-08-11 2026-05-14 Curadev Pharma Pvt Ltd Small molecule urea derivatives as sting antagonists
CN121318920A (zh) * 2022-08-03 2026-01-13 绿叶嘉奥制药石家庄有限公司 5-ht2a受体反向激动剂及其制备方法和应用
WO2024067304A1 (zh) * 2022-09-28 2024-04-04 瀚远医药有限公司 一种具有Sigma2和5HT2A抑制活性的化合物及用途
WO2024105007A1 (en) * 2022-11-15 2024-05-23 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof
KR20260048603A (ko) 2023-08-02 2026-04-10 아카디아 파마슈티칼스 인코포레이티드 세로토닌-수용체 5-ht와 관련된 질환의 치료에서 사용하기 위한 3-(4-사이클로-프로폭시벤질)-1-(2,4-다이플루오로벤질)-1-(1-메틸피페리딘-4-일)유레아
WO2025162237A1 (zh) * 2024-02-02 2025-08-07 绿叶嘉奥制药石家庄有限公司 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998A (en) 1841-03-12 Refrigerator
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
KR100879647B1 (ko) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
JP2005533813A (ja) * 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ,インコーポレーテッド セロトニン受容体作用物質としてのn−置換ピペリジン誘導体
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
US7875609B2 (en) * 2005-11-25 2011-01-25 Galapagos Sasu Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them
TW200831517A (en) 2006-12-15 2008-08-01 Astrazeneca Ab Chemical compounds
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
KR100878446B1 (ko) 2007-06-07 2009-01-13 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
NO2200610T3 (cg-RX-API-DMAC10.html) * 2007-09-21 2018-06-09
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
AU2014369053B2 (en) 2013-12-20 2019-03-14 Institute For Drug Discovery, Llc Substituted amino triazoles, and methods using same
CN104844502B (zh) 2015-06-05 2018-07-31 齐鲁师范学院 一种匹莫范色林的制备方法
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
CN105481757A (zh) 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
WO2019040107A1 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases

Similar Documents

Publication Publication Date Title
JP7628578B2 (ja) 疾患の治療のための化合物、その塩、及び方法
JP6731483B2 (ja) キナーゼ阻害剤として有用な化合物
JP5696142B2 (ja) 新規アザビシクロヘキサン類
JP5394252B2 (ja) ヘテロアリールピロリジニル及びピペリジニルケトン誘導体
EP1802307B1 (en) Pyrrolidine derivatives as histamine receptors ligands
US20080280879A1 (en) Substituted heterocyclic derivatives and their pharmaceutical use and compositions
WO2008032164A2 (en) Benzimidazolone derivatives
DE60127434T2 (de) Benzoxazinonderivative, deren herstellung und verwendung
JP6477484B2 (ja) 含硫黄二環式化合物
ES2289533T3 (es) Derivados de indol con una actividad antipsicotica mejorada.
JP2009514815A (ja) 迅速に解離するドーパミン2受容体アンタゴニストとしてのピペリジン−4−イル−ピリダジン−3−イルアミン誘導体
CN102171206A (zh) 作为mc4激动剂的二氮杂环庚烷和二氮杂环辛烷
JP2006528147A (ja) ヒスタミンh3受容体リガンドとしての置換ピペリジン
NZ553506A (en) Fused tricyclic derivatives for the treatment of psychotic disorders
JPH09124600A (ja) 新規なピペリジン誘導体、これらを得るための方法及びこれらを含有する薬学的組成物
JP2009500366A (ja) ヒスタミンh3アンタゴニストとしてのピラゾロ[3,4−d]アゼピン誘導体
US8618303B2 (en) Pyrrolidine derivatives
JP2007532523A (ja) ヒスタミンh3受容体リガンドとしてのテトラヒドロベンズアゼピン
US8912176B2 (en) Azetidines as histamine H3 receptor antagonists
AU2006295711B2 (en) Aryl-substituted nitrogen-containing heterocyclic compound
NZ761678B2 (en) Compounds, salts thereof and methods for treatment of diseases
JP2009526016A (ja) Cxcr3受容体拮抗物質としてのピペリジン誘導体
CN925 et al. eT TTTCTCCTT
ME01208B (me) Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora